TNFRSF17 and plasma cell myeloma: Biopsy proven BCMA loss at relapse was shown in 8% of patients whereas in another cohort 67% of patients had a reduction in BCMA intensity on myeloma cells following BCMA CAR T cell infusion including 4 out of 9 non-responders [118,119].